Yamato: Lower SINOPHARM (01099) rating to "hold" with a target price of HK$18.
The company's earnings per share for 2026 to 2028 are expected to increase by 4.5%, 5.6%, and 8.5% respectively compared to the previous year, lower than the market expectation by 3% to 6%.
Daiwa released a research report stating that SINOPHARM (01099) revenue has started to stabilize, but there is no clear rebound timetable yet. Retail pharmacy revenue is expected to grow by double-digits year-on-year in 2026. The rating has been downgraded from "outperform the market" to "hold", with the target price lowered from HK$21 to HK$18. It is expected that earnings per share will increase by 4.5%, 5.6%, and 8.5% respectively in 2026 to 2028, which is 3% to 6% lower than market expectations.
Related Articles
.png)
CSPC PHARMA (01093) has received a $25 million research and development milestone payment from AstraZeneca under a strategic collaboration and licensing agreement.
US Stock Market Move | Concept stocks related to optical communication generally fell, with Applied Optoelectronics (AAOI.US) dropping more than 6%.
GUMING (01364) spent HK$5.758 million to repurchase 288,000 shares on July 10th.
CSPC PHARMA (01093) has received a $25 million research and development milestone payment from AstraZeneca under a strategic collaboration and licensing agreement.
US Stock Market Move | Concept stocks related to optical communication generally fell, with Applied Optoelectronics (AAOI.US) dropping more than 6%.
GUMING (01364) spent HK$5.758 million to repurchase 288,000 shares on July 10th.
RECOMMEND
